<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01725958</url>
  </required_header>
  <id_info>
    <org_study_id>NSE 12-PHX-08-NU-02</org_study_id>
    <nct_id>NCT01725958</nct_id>
  </id_info>
  <brief_title>Effects of a Nutritional Supplement Combination on Body Weight Management</brief_title>
  <official_title>A Phase IV, Open-label, Parallel Group, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management Over a 90-day Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmanex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nu Skin Enterprises</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmanex</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title: A Phase IV, Open-label, Single-Center Study on the Effects of a Nutritional Supplement&#xD;
      Combination on Body Weight Management over a 90-day period&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Safety assessment:&#xD;
&#xD;
      Safety will be assessed by changes in blood chemistries/hematology, and adverse events, of&#xD;
      nutritional supplement emergent AEs (TEAEs), classified by severity grade, relatedness to the&#xD;
      nutritional supplement.&#xD;
&#xD;
      Efficacy Assessment:&#xD;
&#xD;
      The objectives of this study are to evaluate the efficacy (changes in body composition and&#xD;
      measurements as well as influence on appetite and quality of life changes) of the nutritional&#xD;
      supplement administered repeatedly throughout the study.&#xD;
&#xD;
      Study Subject Population:&#xD;
&#xD;
      Healthy adult men and women are eligible for participation upon fulfillment of the&#xD;
      inclusion/exclusion criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>-Evaluate the changes in body composition as determined by percent body fat using the Bod Pod</measure>
    <time_frame>90 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the changes in body weight</measure>
    <time_frame>90 days</time_frame>
    <description>Determine the safety and tolerability of a weight loss system and dietary supplements containing ingredients to promote healthy weight&#xD;
Evaluate the changes in body weight as measured by body weight and body composition changes (as determined by BMI as well as changes in body measurements-waist, hip, arm, and ankle circumferences) of a weight loss system and dietary supplements containing ingredients to promote healthy weight.&#xD;
Determine changes in substrate energy utilization&#xD;
Determine subjective measurements of hunger, appetite, feeling of well being during weight loss&#xD;
Determine changes in expansion and return of blood vessels (pulse wave analyzer)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Safety/Effacy</condition>
  <arm_group>
    <arm_group_label>Dietary Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Regimen&#xD;
-The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutritional supplement and protein shakes</intervention_name>
    <arm_group_label>Dietary Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females and Males aged 25-65 years&#xD;
&#xD;
          2. Signed informed consent&#xD;
&#xD;
          3. BMI between 25 and 40 kg/m2&#xD;
&#xD;
          4. A resting normotensive blood pressure is defined as a systolic blood pressure between&#xD;
             90-145 mmHg and a diastolic blood pressure of 50 90 mmHg&#xD;
&#xD;
          5. Use of effective method of contraception by females of childbearing [potential and&#xD;
             agreement to continue to practice an acceptable method of contraception for the&#xD;
             duration of their participation in the study]. Acceptable methods of contraception&#xD;
             include oral, injectable, or implantable contraceptives; intrauterine devices,&#xD;
             diaphragm plus spermicide; abstinence (must agree to use double-barrier method if they&#xD;
             become sexually active), transdermal patch, or any double barrier method including a&#xD;
             vasectomized sexual partner. Women who have had a hysterectomy or tubal ligation at&#xD;
             least 6 months prior to Visit 1 or who have been post-menopausal&#xD;
&#xD;
          6. Ability to speak and understand English&#xD;
&#xD;
          7. Willing to fast the morning of visit where blood samples are taken&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Self-reported chronic condition that may affect subject safety (e.g., diabetes,&#xD;
             cardiovascular disease) or significantly impact product effectiveness (e.g., chronic&#xD;
             fatigue)&#xD;
&#xD;
          2. Pregnancy/suspected pregnancy, breastfeeding or planning to become pregnant during the&#xD;
             course of the study.&#xD;
&#xD;
          3. Use of Antihypertensive medication for less than 4 months or unregulated clinically&#xD;
             blood pressure.&#xD;
&#xD;
          4. Having undergone gastroplasty or bariatric surgery in the past 10 years.&#xD;
&#xD;
          5. Taking medication (e.g., thyroid medication), must be stable for at least four months.&#xD;
&#xD;
          6. Allergies to any ingredients contained in the Nutritional Supplement.&#xD;
&#xD;
          7. Medical treatment for insomnia or depression within 30-days prior to the screening&#xD;
             visit.&#xD;
&#xD;
          8. Tobacco (e.g. cigarettes, chewing tobacco, pipe, nicotine patches) use within 30-days&#xD;
             prior to the screening visit.&#xD;
&#xD;
          9. Planned surgical procedure during the course of the study.&#xD;
&#xD;
         10. Currently participating in another study or have done so within 30 days prior to the&#xD;
             screening visit or is likely to enroll in another clinical or nutritional study.&#xD;
&#xD;
         11. Currently taking any medication or supplement for the use of weight loss must be&#xD;
             discontinued prior to Visit 1 Baseline Day 0.&#xD;
&#xD;
         12. Currently participating in a weight loss program or participated in a weight loss&#xD;
             program in the past 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Poole, BS</last_name>
    <role>Study Director</role>
    <affiliation>Pharmanex</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>October 19, 2012</study_first_submitted>
  <study_first_submitted_qc>November 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2012</study_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01725958
org study id: NSE 12-PHX-08-NU-02
nct id: NCT01725958
lead sponsor: 
collaborator: 
has dmc: Yes
Title: A Phase IV, Open-label, Single-Center Study on the Effects of a Nutritional Supplement
      Combination on Body Weight Management over a 90-day period
Safety assessment:

      Safety will be assessed by changes in blood chemistries/hematology, and adverse events, of
      nutritional supplement emergent AEs (TEAEs), classified by severity grade, relatedness to the
      nutritional supplement.

      Efficacy Assessment:

      The objectives of this study are to evaluate the efficacy (changes in body composition and
      measurements as well as influence on appetite and quality of life changes) of the nutritional
      supplement administered repeatedly throughout the study.

      Study Subject Population:

      Healthy adult men and women are eligible for participation upon fulfillment of the
      inclusion/exclusion criteria.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: -Evaluate the changes in body composition as determined by percent body fat using the Bod Pod
time frame: 90 Days
measure: Evaluate the changes in body weight
time frame: 90 days
description: Determine the safety and tolerability of a weight loss system and dietary supplements containing ingredients to promote healthy weight
Evaluate the changes in body weight as measured by body weight and body composition changes (as determined by BMI as well as changes in body measurements-waist, hip, arm, and ankle circumferences) of a weight loss system and dietary supplements containing ingredients to promote healthy weight.
Determine changes in substrate energy utilization
Determine subjective measurements of hunger, appetite, feeling of well being during weight loss
Determine changes in expansion and return of blood vessels (pulse wave analyzer)
arm group label: Dietary Supplement
arm group type: Experimental
description: Treatment Regimen
-The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake.
intervention type: Dietary Supplement
intervention name: Nutritional supplement and protein shakes
arm group label: Dietary Supplement
criteria: 
gender: All
minimum age: 25 Years
maximum age: 65 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Steve Poole, BS
role: Study Director
affiliation: Pharmanex
facility: 
country: United States
responsible party type: Sponsor
mesh term: Body Weight